Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus Vaccine in Infants 6–7 Months of age: A Phase 1/2 Randomized TrialXavier Sáez‐Llorens, Nicolas Vanhoutte, Ximena Norero et al.|The Journal of Infectious Diseases|2023Cited by 13
Brand-Specific Enhanced Safety Surveillance Study of GSK’s Quadrivalent Seasonal Influenza Vaccine, Conducted During the COVID-19 Pandemic, in Belgium, Germany and Spain, for the 2020/21 SeasonGaël Dos Santos, Ugo Nwoji, Hélène Roul et al.|Infectious Diseases and Therapy|2021Cited by 6